The anti-PD1 immunotherapy nivolumab (Opdivo) given prior to surgical resection of stage 1-3 non-small cell lung cancer (NSCLC) was safe and resulted in major pathological responses in 45 percent of the patients, according ...
Apr 16, 2018
0
2
Non-small-cell lung cancer, the most common type of lung cancer, is the leading cause of cancer death in the U.S. A new study suggests that about 1 in 4 cases, those driven by the KRAS oncogene, could be successfully treated ...
Apr 2, 2018
0
56
A novel approach to studying cancer has enabled researchers to group about 10,000 human cancers of 32 different types into 10 classes based on the molecular pathways that drive tumor growth. A better understanding of these ...
Feb 12, 2018
0
3
Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering ...
Jan 24, 2018
0
164
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...
Dec 12, 2017
0
120
Massachusetts General Hospital (MGH) investigators have identified a way in which a type of lung cancer co-opts a portion of the immune system to increase tumor progression. In the Dec. 1 issue of Science, the team from the ...
Nov 30, 2017
0
103
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy ...
Nov 30, 2017
0
205
Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC). In a study presented in the featured clinical investigation article ...
Nov 6, 2017
0
2
A new UC San Francisco-led study challenges the dogma in oncology that most cancers are caused by one dominant "driver" mutation that can be treated in isolation with a single targeted drug. Instead, the new research finds ...
Nov 6, 2017
0
53
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...
Oct 18, 2017
0
1
